Announcement PDF RNS Number : 0225M Genedrive PLC 18 December 2025 genedrive plc ("genedrive" or the "Company") Genedrive's CYP2C19 ID kit piloted as a "test of change" in Scotland NHS Grampian and Western Isles genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that Genedrive's CYP2C19 ID Kit has been implemented into Scottish NHS Grampian (Dr. Gray's Hospital, Elgin) & NHS Western Isles (Western Isles Hospital, Stornoway) under a "test of change" pilot programme for stroke patients in remote and rural settings. Whilst the pathway for CYP2C19 genotyping in NHS Scotland currently relies on laboratory testing, the Centre For Sustainable Delivery, commissioned by the Scottish Government, are assessing the impact of rapid genetic testing using the Genedrive CYP2C19 ID kit under a "test of change" programme which will run for approximately one year and include c.400 patients. Further details are available at https://shorturl.at/P4i00 Dr Gino Miele, CEO of genedrive plc, said: "We are delighted that the Centre for Sustainable Delivery is assessing the impact of our interventional rapid genetic test solution in NHS Grampian and Western Isles, enabling a precision medicine approach to antiplatelet therapy in these stroke patients in rural settings, and ultimately, significantly better outcomes for patients in these communities. Whilst a relatively small "pilot" programme, it is notable that our interventional test is being explored as a "test of change" and we are confident that the clinical value of our rapid testing solution will continue to be evident and the case for wider deployment in Scotland strengthened." NHS Grampian consultant in stroke/acute medicine and clinical lead for the project, Petrus Elofuke, said: "We are introducing the Genedrive® CYP2C19 ID Kit test as a test of change in Elgin and Stornoway at the same time as samples are sent for lab-based testing. We'll look at how results compare over the next year. It's the first time a device of this kind has been tested in remote and rural settings, and we're extremely proud to be working with colleagues across the two health boards as well as the national Centre for Sustainable Delivery." Clinical lead for the project in NHS Western Isles, David Rigby said: "If the devices deliver proven results over the next year, then our project will inform the business case for revolutionising stroke care for remote and rural patients across Scotland. The Genedrive® devices are the size of a small shoe box and are easily accommodated in smaller rural hospitals. We are very pleased to be working closely alongside manufacturers Genedrive Diagnostics Ltd and providing huge benefit to local patients as we make the case for wider use of this exciting new tech." Jason White the Head of Innovation in the Accelerated National Innovation Adoption (ANIA) team which is part of the NHS National Centre for Sustainable Delivery, said: "This project is a powerful example of how innovation can directly improve patient care, especially in remote and rural communities. By enabling rapid genetic testing at the point of care, we're helping clinicians make faster, more informed decisions about stroke treatment. It's about delivering the right care, in the right place, at the right time and we're proud to support this collaborative effort through the ANIA pathway." Engage with the genedrive management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://investors.genedrive.com/link/PZ3d7y For further information, please contact: Genedrive plc Dr Gino Miele (CEO) Russ Shaw (CFO) We encourage all investors to share questions on this announcement via our investor hub https://investors.genedrive.com/s/e0025c +44 (0) 161 989 0245 Peel Hunt LLP - Nominated Adviser, Joint Broker James Steel +44 (0) 20 7148 8900 Walbrook PR Ltd (Media & Investor Relations) Anna Dunphy https://investors.genedrive.com/s/e0025c +44 (0)20 7933 8780 or genedrive@walbrookpr.com +44 (0)7876 741 001 Subscribe to our news alert service: https://investors.genedrive.com/s/efea03 About genedrive plc (http://www.genedrive.com) genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END MSCEANAXFDPSFFA